Get the Stockscreener App
0.1174
3.93%
-0.0048
After Hours:
.12
0.0026
+2.21%
Windtree Therapeutics Inc stock is traded at $0.1174, with a volume of 2.78M.
It is down -3.93% in the last 24 hours and down -61.15% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$0.1222
Open:
$0.1229
24h Volume:
2.78M
Relative Volume:
0.86
Market Cap:
$1.31M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.00423
EPS:
-27.73
Net Cash Flow:
$-12.72M
1W Performance:
-10.11%
1M Performance:
-61.15%
6M Performance:
-98.93%
1Y Performance:
-67.34%
1-Day Range:
$0.1161
$0.123
1-Week Range:
$0.1046
$0.144
52-Week Range:
$0.1046
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.1174 | 1.31M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms By Investing.com - Investing.com Australia
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MSN
Windtree Therapeutics Reports Q3 Results and Highlights Key Business Achievements - MSN
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic Shock - MSN
Windtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit Committee - Defense World
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy - MSN
Warrington’s Windtree Therapeutics Eyes Acquisitions to Stay Afloat - MSN
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - The Manila Times
Windtree Therapeutics Secures Key Japanese Patent for Novel Cancer Treatment Platform - StockTitan
Windtree Therapeutics appoints new board member By Investing.com - Investing.com Australia
Windtree Therapeutics, Inc. Appoints Leanne Kelly to Its Board of Directors and Chair of the Audit Committee - Marketscreener.com
Windtree Therapeutics Strengthens Leadership Amid Strategic Shift - TipRanks
Windtree Therapeutics appoints new board member - Investing.com
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - Yahoo Finance
Windtree Therapeutics Inc (WINT): Worth A Small Bite At $0.27 - Stocks Register
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MSN
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
Windtree Therapeutics adopts new acquisition strategy By Investing.com - Investing.com Nigeria
Windtree Therapeutics seeks acquisitions to stop slide as stock hits new low - The Business Journals
Windtree Therapeutics adopts new acquisition strategy - Investing.com India
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - The Manila Times
Windtree Therapeutics Unveils Bold Revenue Strategy: Plans FDA-Approved Product Acquisitions - StockTitan
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials - MSN
WINT stock touches 52-week low at $0.29 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest - Defense World
WINT stock touches 52-week low at $0.32 amid steep annual decline - Investing.com
Windtree Announces Istaroxime Presentation By Cardiogenic - GlobeNewswire
Windtree's Istaroxime Shows Breakthrough Results in Phase 2 Heart Failure Trials, Advances to Phase 3 - StockTitan
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):